ClearPoint Neuro (CLPT) announced its partner, Clinical Laserthermia Systems, completed the submission of its 510(k) application to the FDA, expanding the indication of the ClearPoint Prism Neuro Laser Therapy System to include 1.5 T MRI guidance. ClearPoint Prism has already seen rapid adoption across functional and oncological neurosurgical LITT procedures. ClearPoint Prism is currently indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy under 3.0 T magnetic resonance imaging guidance in medicine and surgery in neurosurgery for a wavelength of 1064nm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue